# Parameswaran Hari

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/parameswaran-hari/

## Facts

| Field | Value |
| --- | --- |
| Citations | 26,801 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 79 |
| i10-index | 354 |
| Last Known Institution | Medical College of Wisconsin |
| OpenAlex ID | https://openalex.org/A5031690184 |
| ORCID iD | https://orcid.org/0000-0002-8800-297X |
| Works | 914 |

## Researcher papers

- [Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study](https://scholariq.org/papers/ciltacabtagene-autoleucel-a-b-cell-maturation-antigen-directed-chimeric-antigen/)
- [Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study](https://scholariq.org/papers/belantamab-mafodotin-for-relapsed-or-refractory-multiple-myeloma-dreamm-2-a-two/)
- [Current Use of and Trends in Hematopoietic Cell Transplantation in the United States](https://scholariq.org/papers/current-use-of-and-trends-in-hematopoietic-cell-transplantation-in-the-united/)
- [Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study](https://scholariq.org/papers/efficacy-and-safety-of-lifileucel-a-one-time-autologous-tumor-infiltrating/)
- [Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies](https://scholariq.org/papers/long-term-outcomes-among-older-patients-following-nonmyeloablative-conditioning/)
- [Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial](https://scholariq.org/papers/autologous-transplantation-consolidation-and-maintenance-therapy-in-multiple/)
- [Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-pomalidomide-and-dexamethasone-for-patients-with-relapsed-or/)
- [Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation](https://scholariq.org/papers/graft-versus-host-disease-and-graft-versus-tumor-effects-after-allogeneic/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Hematopoietic Stem Cell Transplantation](https://scholariq.org/topics/hematopoietic-stem-cell-transplantation/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)

## Researcher university

- [Medical College of Wisconsin](https://scholariq.org/institutions/medical-college-of-wisconsin/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.